BioTuesdays

Category - Markets

DermTech-Logo
Markets

Cowen starts DermTech at OP; PT $20

Cowen launched coverage of DermTech (NASDAQ:DMTK) with an “outperform” rating and $20 price target. The stock closed at $10.65 on Sept. 9. DermTech provides the only commercial-stage genomics-based non-invasive solution...

September 10, 2020
Motus GI Holdings
Markets

AGP ups Motus GI Holdings PT to $2.60 from $1.65

Alliance Global Partners raised its price target for Motus GI Holdings (NASDAQ:MOTS) to $2.60 from $1.65, “rolling our valuation multiple onto our newly introduced 2022 estimates and utilizing 50 million as our share...

September 9, 2020
Corbus Pharmaceuticals
Markets

HCW reduces Corbus Pharma PT to $6 from $24

H.C. Wainwright slashed the price target for Corbus Pharmaceuticals (NASDAQ:CRBP) to $6 from $24 but maintained its “buy” rating after the company’s Phase 3 RESOLVE-1 trial of lenabasum in cutaneous systemic sclerosis...

September 9, 2020
Markets

HCW starts Surface Oncology at buy; PT $11

H.C. Wainwright launched coverage of Surface Oncology (NASDAQ:SURF) with a “buy” rating and $11 price target. The stock closed at $6.40 on Sept. 3. Surface is developing cancer therapies targeting checkpoints that...

September 4, 2020
Alphatec Spine Logo
Markets

Cowen starts Alphatec Spine at OP; PT $12

Cowen launched coverage of Alphatec Spine (NASDAQ:ATEC) with an “outperform” rating and $12 price target. The stock closed at $6.09 on Sept. 2. Alphatec designs, develops, manufactures and markets surgical spine...

September 3, 2020
Constellation Logo
Markets

Brookline starts Constellation Pharma at buy; PT $33

Brookline Capital Markets initiated coverage of Constellation Pharmaceuticals (NASDAQ:CNST) with a “buy” rating and $33 price target. The stock closed at $21 on Sept 2. Constellation is using epigenetics to address...

September 3, 2020
Acasti Pharma
Markets

Echelon cuts Acasti Pharma to sell; PT to 15 cents

Echelon Wealth Partners downgraded Acasti Pharma (TSXV:ACST) to “sell” from “speculative buy” and slashed its price target to 15 cents (Canadian) from $1.40 after the company reported that its Phase 3 TRILOGY 2 trial...

September 1, 2020
Acutes-Medical-Logo
Markets

Analysts start Acutus Medical at hold, buy, OP

Analysts for Canaccord Genuity, BTIG and William Blair launched coverage of Acutus Medical (NASDAQ:AFIB) with “hold”, “buy” and “outperform” ratings, respectively.  Acutus is a pure-play electrophysiology company...

August 31, 2020
Brookline Logo
Markets

Brookline starts Forte Biosciences at buy; PT $90

Brookline Capital Markets launched coverage of Forte Biosciences (NASDAQ:FBRX) with a “buy” rating and $90 price target. The stock closed at $26.69 on Aug. 27. Forte Biosciences is developing FB-401, a topical live...

August 28, 2020